导师姓名： 吴凌云 专业代码： 100201
性别： 女 专业名称： 内科学
培养单位： 附属第六人民医院 三级学科/
专业领域： 血液病
导师类型： 博士生导师 专业学位导师： 兼
联系方式：
邮编： 邮箱地址： lincy2032@163.com

研究方向 (点击浏览详细信息)
骨髓增生异常综合征发病机制及诊治

社会任职
中国老年医学血液分会MDS学组秘书
中华医学会上海市血液学分会青年委员

科研项目 项目编号项目名称课题来源起止年月批准经费承担职责
** ROBO1基因突变通过CDC42/PAK1调控MDS细胞恶性生物学特征的分子机制 国家自然科学基金 2017-01~2020-12 60万元 课题负责人
2ZR** 核糖体蛋白RPL23在MDS发病中的作用 上海市自然科学基金 2013-01~2015-12 10万元 课题负责人
** 核糖体蛋白RPL23通过Miz1/c-Myc分子途径参与骨髓增生异常综合征发病的机制研究 国家自然科学基金 2013-01~2015-12 23万元 课题负责人

学术论文 作者论文标题期刊名出版年卷期页码
朱屿倩,吴凌云 （通讯作者） 骨髓增生异常综合征患者中U2AF1基因突变的研究进展 国际输血及血液学杂志 2019 42(2): 149-153
宋丹丹,常春康,郭娟,许峰,赵佑山,吴凌云 （通讯作者） 骨髓增生异常综合征患者骨髓巨噬细胞百分比异常及其意义 诊断学理论与实践 2018 17(4):439-443.
Hayashi Y, Zhang Y, Yokota A, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger GM, Wang J, Dong Y, Zhou Y, Wang J, Wu L, Bu J, Chen A, Zhao X, Sun X, Chetal K, Olsson A, Watanabe M, Romick-Rosendale LE, Harada H, Shih LY, Tse W, Bridges JP, Caligiuri MA, Huang T, Zheng Y, Witte DP, Wang QF, Qu CK, Salomonis N, Grimes HL, Nimer SD, Xiao Z, Huang G. Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Cancer Discov. 2018 8(11):1438-1457
Zheng Q, Zhao Y, Guo J, Zhao S, Fei C, Xiao C, Wu D, Wu L, Li X, Chang C. Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway. Cell Death Dis. 2018 9(5):515.
Huang R, Hayashi Y, Yan X, Bu J, Wang J, Zhang Y, Zhou Y, Tang Y, Wu L, Xu Z, Liu X, Wang Q, Zhou J, Xiao Z, Bridges JP, Marsh RA, Zhang K, Jordan MB, Li Y, Huang G. HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis. Haematologica. 2017 102(11):1956-1968
吴凌云,祁岳坤,许峰,赵佑山,李晓,常春康 349例骨髓增生异常综合征患者U2AF1基因突变的临床研究 中华血液学杂志 2017 38(01): 68-70.
Qi Y, Li X, Chang C, Xu F, He Q, Zhao Y, Wu L. （通讯作者） Ribosomal protein L23 negatively regulates cellular apoptosis via the RPL23/Miz-1/c-Myc circuit in higher-risk myelodysplastic syndrome. Scientific Reports 2017 7(1):2323.
宋丹丹,吴凌云 （通讯作者） 巨噬细胞在红系造血中的作用 中国实验血液学杂志 2017 25(4):1223-1226
Xu F, Wu LY （共同第一作者）, He Q, Wu D, Zhang Z, Song LX, Zhao YS, Su JY, Zhou LY, Guo J, Chang CK, Li X. Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes. Sci. Rep. 2017 7:43113
Wu L, Shi W, Li X, Chang C, Xu F, He Q, Wu D, Su J, Zhou L, Song L, Xiao C, Zhang Z. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. J Transl Med. 2016 14:66
Wu L, Song L, Xu L, Chang C, Xu F, Wu D, He Q, Su J, Zhou L, Xiao C, Zhang Z, Zhao Y, Chen S, Li X. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. Tumour Biol. 2016 37(4):4633-40
Wu L, Li X, Chang C, Xu F, He Q, Wu D, Zhang Z, Su J, Zhou L, Song L, Chao X, Zhao Y. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study. Leuk Lymphoma. 2016 57(6):1367-74.
Xu F, Wu LY （共同第一作者）, Chang CK, He Q, Zhang Z, Liu L, Shi WH, Guo J, Zhu Y, Zhao YS, Gu SC, Fei CM, Wu D, Zhou LY, Su JY, Song LX, Xiao C, Li X. Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes. Nature Communications 2015 6:8806.
张耀,宋陆茜,吴凌云 （通讯作者）,常春康,李晓 p15INK4B甲基化与骨髓增生异常综合征患者预后及地西他滨疗效的关系 中华血液学杂志 2013 34(3) :237-241
Wu L, Li X, Xu F, Zhang Z, Chang C, He Q. Low RPS14 expression in MDS without 5q - aberrationconfers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response tolenalidomide in lower risk non-5q- patients European Journal of Hematology 2013 90(6):486-493
Wu L, Li X, Xu F, Chang C, He Q, Zhang Z, Zhang Y. Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34(+) cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine. Ann Hematol. 2012 91 (10):1547-1554
Zhang Y, Wu L （共同第一作者）, et al. Low RPS14 gene expression is accompanied by p53-independent apoptosis in MDS patients with 5q- aberrations. HealthMED 2012 6(7):2456-2463
Wu L, Li X, Su J, He Q, Zhang X, Chang C, Pu Q. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS. J Cancer Res Clin Oncol 2011 137(10):1563-9.
Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma 2009 50(9):1461-7